Wanner, Adam, Eliana S. Mendes, and Neal D. Atkins. A simplified noninvasive method to measure airway blood flow in humans. J Appl Physiol 100: 1674 -1678, 2006; doi:10.1152/japplphysiol.01349.2005.-Our laboratory has previously developed and validated a noninvasive soluble gas uptake method to measure airway blood flow (Q aw) in humans (Onorato DJ, Demirozu MC, Breitenbücher A, Atkins ND, Chediak AD, and Wanner A. Am J Respir Crit Care Med 149: 1132-1137 Scuri M, McCaskill V, Chediak AD, Abraham WM, and Wanner A. J Appl Physiol 79: 1386 -1390, 1995. The method has the disadvantage of requiring eight breath-hold maneuvers for a single Qaw measurement, a complicated data analysis, and the inhalation of a potentially explosive gas mixture containing dimethylether (DME) and O 2. Because of these shortcomings, the method thus far has not been used in other laboratories. We now simplified the method by having the subjects inhale 500 ml of a 10% DME-90% N2 gas mixture to fill the anatomical dead space, followed by a 5-or 15-s breath hold, and measuring the instantaneous DME and N2 concentrations and volume at the airway opening during the subsequent exhalation. From the difference in DME concentration in phase 1 of the expired N2 wash-in curve multiplied by the phase 1 dead space volume and divided by the mean DME concentration and the solubility coefficient for DME in tissue, Qaw can be calculated by using Fick's equation. We compared the new method to the validated old method in 10 healthy subjects and found mean Ϯ SE Q aw values of 34.6 Ϯ 2.3 and 34.6 Ϯ 2.8 l ⅐ min Ϫ1 ⅐ ml Ϫ1 , respectively (r ϭ 0.93; upper and lower 95% confidence limit ϩ2.48 and Ϫ2.47). Using the new method, the mean coefficient of variation for two consecutive measurements was 4.4% (range 0 -10.4%); inhalation of 1.2 mg albuterol caused a 53 Ϯ 14% increase in Q aw (P ϭ 0.02) and inhalation of 2.4 mg methoxamine caused a 32 Ϯ 7% decrease in Q aw (P ϭ 0.07). We conclude that the new method provides reliable values of and detects the expected changes in Q aw with vasoactive drugs. The simplicity and improved safety of the method should improve its acceptability for the noninvasive assessment of Q aw in clinical research.
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bronchial blood flow; soluble gases; adrenergic agents OUR LABORATORY HAS PREVIOUSLY DEVELOPED a noninvasive soluble gas uptake method for the measurement of blood flow in the airway mucosa [airway blood flow (Q aw)] of humans (9) and validated its accuracy with microspheres in sheep (13) . The method is based on quantifying the disappearance of the soluble gas dimethylether (DME) from the anatomical dead space. The method involves inhalation of a gas mixture containing DME, helium, and O 2 , followed by multiple breathhold times and subsequent exhalation into a spirometer while the instantaneous concentrations of DME (F DME ), helium, and nitrogen (N 2 ) are recorded along with the expired volume. From these parameters, Q aw can be calculated according to Fick's principle. Q aw values are expressed as microliters per minute per milliliter, where "milliliter" reflects the anatomical dead space volume (VD) (minus the most proximal 20 -50 ml to exclude upper airway uptake). One Q aw determination takes ϳ7 min. This technique has been used in our laboratory in several studies involving healthy subjects and patients with airway disease (1, 2, 5, 6 -8, 11) .
Although this is the only currently available reliable noninvasive method to assess Q aw, it has the disadvantage of requiring eight breath-hold maneuvers for a single Qaw measurement, a complicated data analysis, and the inhalation of a gas mixture containing both DME and O 2 . As a result, an elaborate test apparatus is needed to prevent the possibility of accidentally igniting the gas mixture with an electrical component. Because of these shortcomings, the method thus far has not been used in other laboratories.
Recently, we introduced a new way to analyze the gas concentration and volume tracing. In the old analysis, the helium dilution-corrected mean fractional DME concentration (F DME ) in the anatomical dead space volume after four different breath-hold times (5, 10, 15, and 20 s) was used to calculate DME uptake from the anatomical dead space volume and Q aw by Fick's equation. Because each of the four breath holds was repeated, eight breath-hold maneuvers were required per Q aw measurement. In the new analysis, the decline in F DME is determined at or toward the end of phase 1 of the expired N 2 curve after a short (e.g., 5-s) and long (e.g., 15-s) breath-hold period. With this approach, there is no need for helium and O 2 in the gas mixture, only two breath holds are needed, the gas signals do not have to be integrated, and a safe 10% DME-90% N 2 mixture can be used. Because the inspired N 2 concentration is higher than the alveolar N 2 concentration, the end of phase 1 can be identified on the expired N 2 curve (single-breath N 2 wash-in).
In this paper we describe the new, simplified DME uptake method for the measurement of Q aw and report the results of its validation by comparing Q aw values obtained with the old and new methods and by assessing the reproducibility of Q aw and determining Q aw responses to vasoactive agents using the new method. With this approach, we expected to show that the new method is feasible, reproducible, and sensitive to intervention.
MATERIALS AND METHODS

Theoretical Considerations
DME is soluble in tissue and blood (12) . If a volume of DME is inhaled that is large enough to fill VD, the disappearance of DME from the dead space during a subsequent breath hold is due to DME equilibration with tissue lining the airway, blood flow through that tissue (Q aw), and axial DME diffusion into the alveolar space where F DME is low because of DME dilution and uptake by pulmonary blood flow. Assuming that DME equilibration with airway tissue is complete within seconds and that axial DME diffusion does not occur in the VD corresponding to phase 1 of the single-breath N2 washout or wash-in curve (VD1), the uptake of DME from VD1 between a 5-s and 15-s breath hold must be proportional to Q aw in that segment of the conducting airways (Fig. 1) . With this approach, the transient, tissue equilibration-dependent DME uptake and alveolar gas contamination can be ignored.
Using Fick's equation for blood flow calculation, Q aw ϭ V DME/ (FDME ⅐ ␣), where VDME is DME uptake from VD1 during the 10 s between the 5-s and 15-s breath-hold period, FDME is the mean fractional DME concentration in VD1 between the two breath holds, and ␣ is the Bunsen solubility coefficient for DME in tissue and blood at 37°C (12) . The DME uptake from VD 1 is obtained from the difference in FDME in VD1 minus the first 20 ml of the exhaled volume to exclude oropharyngeal (defined as the combined epipharyngeal, mesopharyngeal, hypopharyngeal, and oral cavity) DME uptake between the two breath-hold periods, multiplied by VD 1 (minus 20 ml) and divided by 10 s. Finally, Q aw is divided by VD1 (minus 20 ml) to normalize for the airway volume in which Q aw is determined; Qaw is expressed as microliters per minute per milliliter.
New Method to Measure Q aw
Apparatus. The equipment used to measure Q aw consisted of a pneumatic multiport valve system whose ports were connected to a mouthpiece, to a Teflon bag to hold the test gas mixture (10% DME-90% N 2, purchased premixed from Praxair, Danbury, CT), and to atmosphere (Fig. 2) . Between the valve system and the mouthpiece, a pneumotachograph (connected to a differential pressure gauge and demodulator; Validyne, Northridge, CA) was inserted, and the instantaneous concentrations of DME and N 2 were measured in the mouthpiece by use of a mass spectrometer (Perkin-Elmer, Pomona, CA). This reduced the relevant external dead space to 6 ml. The pneumotachograph was calibrated with the test gas. A computer provided with analog-to-digital converters was used to control the filling of the Teflon bag and the sequence of the solenoids regulating the pneumatic valve system, to integrate the flow signal, and to calculate Qaw from the expired volume and integrated gas concentration signals as described above. The inspired DME concentration was monitored to ensure reproducible values for the 5-s and 15-s breath-hold pairs. The mass spectrometer inlet was not heated, and no corrections were made for water pressure. The resulting overestimation of F DME was considered to be negligible (ϳ0.003).
Procedure. Subjects (wearing a nose clip) inhaled room air through the mouthpiece to total lung capacity position, exhaled 500 ml and then inhaled 500 ml of the test gas mixture back to total lung capacity position in rapid sequence. The airway was occluded at this point. They then held their breath for either 5-s or 15-s in random order. After each of the breath-hold periods, the subjects exhaled through the port with the critical flow orifice (to standardize expiratory flow rate at 0.25 l/s), and air flow and gas concentrations were measured during this maneuver. The elapsed time between the two breath holds was less than 1 min.
Data analysis and calculation of Q aw. As shown in Fig. 1 , Q aw is determined from the exhaled volume (V), DME, and N 2 signals. Expiration through a critical flow orifice after a 5-s and 15-s breath hold starts at t0. The end of phase 1 on the N2 washout curve is reflected by t2. At this time point, the phase 1 dead space (VD1) has been expired. t1 is the time point at which the oropharyngeal volume has been expired (20 ml). The dead space of interest is the volume expired between t1 and t2 (VD1 Ϫ 20 ml). The mean DME concentration between t1 and t2 is lower after the 15-s than 5-s breath hold owing to DME uptake during the 10 s that have elapsed between them. F DME 5 ϭ ͑F DME t 1 ϩ F DME t 2 ͒/2 F DME 15 ϭ ͑F DME t 1 ϩ F DME t 2 ͒/2 ⌬F DME ϭ F DME 5 Ϫ F DME 15 F DME ϭ ͑F DME 5 ϩ F DME 15 ͒/2 V DME ϭ ͑VD 1 Ϫ 20 ml) ⅐ ⌬F DME Q aw ϭ V DME /͑F DME ⅐ ␣ ⅐ 10 s͒ where ␣ is the DME solubility coefficient (9 ml/ml) and Q aw is expressed in milliliters per second. Normalizing Q aw for the dead space volume from which DME uptake is measured (VD 1 Ϫ 20 ml), the equation reduces to Q aw ϭ ⌬F DME /͑F DME ⅐ ␣ ⅐ 10 s͒.
To express Q aw as microliters per minute per milliliter dead space, the obtained value is multiplied by 6 and 1,000.
Protocol and Subjects
Healthy lifetime nonsmokers who did not have a history of cardiovascular or lung disease and were not taking vasoactive or airway Fig. 1 . Stylized dimethylether (DME), N2, and volume (V) curves reflecting the last few seconds of a 5-s and 15-s breath hold (DME5 and DME15, respectively). t0, Beginning of expiration after breath hold; t1, time point at which upper airway volume has been expired; t2, end of phase 1 (obtained from N2 curve). Note that the inspired N2 concentration (90%) is higher than the alveolar N2 concentration. drugs were recruited for the study. The subjects were instructed to abstain from ingesting alcoholic beverages the night before and not to ingest coffee or caffeinated drinks on the day of the study. The study was approved by the Institutional Review Board, and subjects signed an informed consent and HIPAA form B.
Study 1. In this study, the original and new method of data analysis was compared. Ten subjects (6 women, mean age 39 yr, range 27-59) participated. Q aw was measured by using the original protocol and gas mixture, and the value obtained with the original calculation (8 breath holds) was compared with the value obtained with the new calculation (5-and 15-s breath hold).
Study 2. The purpose of this protocol was to assess the reproducibility and vasoactive drug responsiveness of Q aw using the new method. Ten subjects took part in this study ( Table 1) . Four of these also participated in study 1.
There were two visits to the laboratory. VISIT 1. Q aw was measured twice, less than 5 min apart (reproducibility assessment). Thereafter, the subjects inhaled either 1.2 mg albuterol or 2.4 mg methoxamine (delivered doses), chosen randomly. Q aw was remeasured 15 min later (we have previously shown that the vasoconstrictor and vasodilator effects of inhaled methoxamine and albuterol at these doses peak between 5 and 15 min after inhalation and have passed by 30 min; Refs. 1, 4). The aerosols of albuterol and methoxamine were generated with a DeVilbiss nebulizer connected to a dosimeter. Solutions of the two drugs in phosphate-buffered saline were freshly prepared on each experiment day, and the generated dose was calculated from the number of breaths and the drug concentration in the nebulized solution (4). The subjects inhaled the aerosols tidally from functional residual capacity. The study was single blinded, i.e., the subjects did not know which adrenergic agonist they inhaled on a given day. The effects of the buffered saline vehicle were not assessed because saline inhalation has previously been shown not to alter Qaw (10) .
Systemic blood pressure and pulse rate were measured before each Q aw determination. Although the inhalation of 500 ml of an O 2-free gas mixture is not expected to cause transient hypoxemia (a portion of the 500 ml ends up in VD, where there is no appreciable gas exchange, and the remainder is added to a large alveolar volume, thereby only minimally lowering alveolar O 2 concentration), pulse oximetry was carried out before and for 2 min after the 15-s breath hold (first Q aw determination in the reproducibility test). VISIT 2. On this visit, the subjects inhaled the alternate adrenergic agonist, and Q aw, blood pressure, and pulse rate were measured before and after drug inhalation as on visit 1.
Statistical Analysis
The data (mean Ϯ SE) were analyzed with ANOVA. The significance level was P Ͻ 0.05.
RESULTS
Study 1
Mean Q aw was 34.6 Ϯ 2.3 l ⅐min Ϫ1 ⅐ml Ϫ1 with the new calculation method and 34.61 Ϯ 2.8 l⅐min Ϫ1 ⅐ml Ϫ1 with the original calculation method. In 9 of the 10 subjects, the values fell within Ϯ15% of the line of identity, and the correlation coefficient was 0.93 (Fig. 3) . The 95% confidence limits were ϩ2.48 and Ϫ2.47 l⅐min Ϫ1 ⅐ml Ϫ1 (Bland-Altman comparison plot).
Mean VD 1 was 93 Ϯ 6 ml and 96 Ϯ 10 ml when obtained from the 5-s and 15-s breath-hold tracings, respectively [P ϭ not significant (NS)]. In contrast, VD as determined with the Fowler technique (3) was higher when determined with the 5-s than with the 15-s breath-hold maneuver (299 Ϯ 16 ml vs. 270 Ϯ 11 ml; P Ͻ 0.05). This indicates that VD 1 did not change during the 10-s time period used to calculate V DME , whereas the measured VD decreased with the longer breath-hold time, presumably because of a change in the slope of phase 3 on the N 2 washout or wash-in curve as a result of gas mixing between alveoli and airways in the lung periphery.
Study 2
Reproducibility. Mean Q aw measured consecutively with the new method was 33.2 Ϯ 3.0 and 32.0 Ϯ 3.2 l⅐min Ϫ1 ⅐ml Ϫ1 , respectively ( Table 1 ). The mean coefficient of variation was 4.4% (range 0 -10.4%); 7 of 10 fell within Ϯ5%, 1 of 10 within Ϯ10%, and 2 of 10 within Ϯ15% of the line of identity. Mean O 2 saturation was 98.8 Ϯ 0.2% before and 98.6 Ϯ 0.3% 2 min after termination of the 15-s breath hold (P ϭ NS); the O 2 saturation did not fall by more than 1% in any of the subjects during the 2-min observation period.
Adrenergic responsiveness of Q aw. Mean Q aw increased by 53 Ϯ 14% after albuterol (P ϭ 0.02) and decreased by 32 Ϯ 7% after methoxamine (P ϭ 0.07) ( Table 2 ). The corresponding mean absolute changes in Q aw were ϩ18.9 Ϯ 4.4 and Ϫ13.3 Ϯ 3.1 l⅐min Ϫ1 ⅐ml
Ϫ1
. Mean systolic/diastolic blood Q aw, airway blood flow; F, female; M, male; SD, standard deviation; CV, coefficient of variation. Two measurements (Q aw1 and Q aw2) were taken Ͻ5 min apart. Q awm, mean of Q aw1 and Q aw2.
DISCUSSION
The new noninvasive method described in this study provides a reliable, quantitative assessment of blood flow in conducting airways while being simpler to perform and inherently safer than the original method (5, 9). Comparing Q aw values obtained with the two methods in the same subjects revealed a high degree of congruence. The original method has been validated in sheep with color-coded microspheres and therefore was considered to be the standard in this study (14) . Furthermore, we found a considerable level of reproducibility of the values with the new method as well as the expected changes in Q aw in response to inhaled adrenergic drugs (2) .
The new method requires only two gases, DME and N 2 (which can be purchased premixed), a volume-measuring device, a valve system that can be automated or manually operated, and a signal recording unit. In addition, a rapidly responding gas analyzer for the instantaneous measurement of DME and N 2 must be available; currently, mass spectrometers are best suited for this purpose. In contrast to the eight breath holds used in the original method, only two breath holds are needed and the data analysis does not require signal integration. Therefore, the results can be calculated by hand and the use of a computer is a matter of convenience, not a necessity. Indeed, only the volume signal has to be calibrated because ⌬F DME and F DME appear as a ratio in the equation to calculate Q aw, and the N 2 signal is used merely to detect the end of phase 1 on the N 2 wash-in curve. If F DME does not slope between t 0 and t 1 (Fig. 1) , there is no need to subtract an oropharyngeal volume from VD 1 and the volume signal does not have to be calibrated. In this case, VD 1 cancels out in the volume-corrected Q aw equation, and Q aw ϭ (⌬F DME / F DME )⅐667, where 667 is (60⅐ 10 3 )/(9⅐10), to obtain blood flow per minute. The unit for Q aw would be min Ϫ1 but is better expressed as microliters per minute per milliliter for conceptual clarity. The analysis assumes that the inspired DME concentration is the same for both breath-hold maneuvers. This is guaranteed by using a premixed gas supply. To prevent gas separation in the reservoir bag, we used a magnetic agitator connected to the bag.
Some of the theoretical and practical limitations of the original method for the measurement of F DME also apply to the new method (1). They include DME equilibration with and diffusion in airway tissue, recirculation of DME, the airway depth captured by the measurement of Q aw, the hemodynamic effects of DME, and the influence of airway caliber on Q aw as measured with this technique.
The uptake of DME from the airway lumen consists of two phases, an initial transient state (during which DME dissolves in tissue and capillary blood and F DME reaches an equilibrium between the airway lumen and tissue/blood), and a steady state that is proportional to blood flow. Although the rate at which DME permeates the airway tissue during the transient state depends on the diffusivity of DME, one can assume that the amount of DME in tissue is relatively constant from the beginning of the steady state, decreasing only slightly in relation to the decrease in luminal F DME during the breath hold. Onorato et al. (9) have shown that the steady state is reached within 2 s. Therefore, V DME should reflect blood flow and be relatively independent of diffusivity during the steady state. The good correlation between Qaw measured with DME and Qaw measured with microspheres in sheep is in keeping with this assumption (13) .
Axial diffusion could have accounted for some of the DME uptake from VD 1 . Onorato et al. (9) examined this in an artificial airway and found stable DME concentrations for up to 20 s. That model did not realistically mimic in vivo conditions because of the absence of cardiogenic oscillations, which have a gas-mixing effect. However, the mixing effect probably would counteract rather than potentiate any gas concentration gradient along the airway. That observation and our limiting DME uptake to VD 1 suggest that peripheral airway and pulmonary blood flow was not included in our measurements. We subtracted a proximal air volume of 20 ml to exclude oropharyngeal DME uptake. To our knowledge, upper airway volume measurements during breath hold have not been reported. Recently, McRobbie and Pritchard (6), who used magnetic resonance imaging to quantitate oropharyngeal air volume in adults breathing tidally through a mouthpiece, found a mean value of 38 ml. Therefore, our Q aw measurements could have included a small fraction of oropharyngeal blood flow.
In the original method, 35% DME was used in the test gas mixture, and there was a concern that a capillary backpressure of DME could build up during the longer breath-hold periods (9) . In the new method, 10% DME is used and the longest breath hold lasts 15-s. Subtracting the expired DME volume from the inspired DME volume (50 ml), we estimated a total DME uptake of 15 ml during the 15 breath-hold maneuver. Considering a dilution of this amount of DME by the cardiac output, the resulting DME backpressure in the airway capillaries must be negligible.
Hlastala (4) showed in rats in whom a subcutaneous gas pocket of diethyl ether was created that in the absence of tissue perfusion, the partial pressure of the gas falls by Ͻ25% within a tissue depth of 200 m. Because DME has a molecular weight and tissue solubility similar to diethyl ether, we believe that the DME uptake method measures airway blood flow to a depth of ϳ200 m, i.e., in the subepithelial tissue. In sheep, 85% of total bronchial blood flow is distributed to this anatomical structure in the airway wall (10) . It is likely that this applies to the human airway as well.
The pharmacological profile of DME includes vasodilation; the magnitude of this action in the airway circulation cannot be estimated in humans. However, the above-mentioned correlation between the DME and microsphere method to measure Q aw in sheep suggests that the local hemodynamic effect of DME is likely to be small. Values are means Ϯ SE; n ϭ 10 subjects. *P ϭ 0.02; †P ϭ 0.07.
Although Q aw is normalized for VD 1 , this does not correct for differences in airway caliber. For example, in the presence of airway narrowing, VD 1 is distributed to a greater depth into the bronchial tree where the mucosal surface-airway lumen area and hence DME uptake is greater. The magnitude of this artifact is not known but likely to be small because VD and VD 1 have been similar in healthy and asthmatic subjects and did not change after albuterol inhalation in a previous study involving the DME uptake technique (5) .
We conclude that the new method to quantify Q aw is feasible, reproducible, and sensitive to changes in Q aw. Because of its simplicity, it lends itself to the study of airway vascular responses in health and disease.
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